|
Company Overview
The continuous advances in modern medicine and bio-research are achieved by refining current and establishing novel methods, procedures, strategies and principles for answering practical questions from the fundamental research and applied medical practice - now more than ever focused on molecular level detecting, finding and purifying individual genes, proteins and their associations.
Because all further advances in the molecular-biotechnology level would relay not only on routine detection, crystallographical and genetical methods, but based on novel approaches, conceptions and methodologies capable of providing information about sub-molecular and quantum changes in the conformational behaviour and energy-transfer relations between molecules in vivo, Regon Molecular Systems, Inc. have a dedicated strategy in discovering new methodologies, design principles and mechanisms. Our goals are the novel design and major improvement of critically important biological methodologies and techniques, discovery of more advanced principles, technologies, devices and products dedicated to further improvements in medical and biotechnological research. Regon Molecular Systems, Inc. is dedicated to developing state-of-the-art technologies for acquiring, analyzing and managing complex genetic information for use in biomedical research. Our products and services implement a wide variety of exceptional novelties in the following areas of biotechnology market:
ð Complex genomic- and technological information Classification and Utilization. ð Nucleic acids, protein, small molecule and tissue Arrays and Exploration Kits. ð Oligonucleotide Annealing and Primed-polymerase-reactions Enhancement. ð Advancement of genetic material Isolation and Amplification. ð Developing and marketing proprietary DNA probe based tests to clinicians and researchers.
Oligonucleotide annealing process and kinetics plays critical role, practically, in all related diagnostics and research applications including RT-PCR and all PCR variations from very-small target-sample amounts, all nucleic acid-based microarray- and in-situ hybridization reactions and labeled probe preparations and many other reactions and methodologies implementing complementary binding reactions of nucleic acids, usually called annealing reaction. Entirely new original conditions for significant annealing improvement and enhancement were discovered (based on a theory mathematically predicted by an outstanding Russian physicist several years ago) and are basis for original (Reverse Transcription) RT-Machine construction. These lead to 5-10-times yield increase of the RT-product utilizing total RNA template amounts below 1 microgram (down to 1 pg) and up to 5-10 times annealing time decrease for all annealing-based reactions (hybridization, etc.) leading to increased annealed nucleic-acid-probe amounts. In comparison, the regular RT primer annealing with total RNA amounts below 100 ng is so unefficient, that for the moderate- and very-low-expressed mRNAs has no practical value, making any microarray-applications irrelevant for them - due to both low sensitivity and reproducibility. With Regon's futures pioneering technological efforts, nonradioactive DNA detection has matured to a state where direct detection of pathogens in clinical samples can be accomplished in a timely and cost-effective manner by utilizing universal microarray-based kits. Regon Molecular Systems, Inc., headquartered in Chicago, Illinois, is a privately held company focused on the detection, measurement and analysis of biological interactions, which serves as the fundamental basis for a broad array of in vitro test systems within the pharmaceutical, biotechnology, genomics and diagnostics industries. Regon Molecular Systems has developed the NewGeneration RT-priming Technology™, an ultra-enhanced Reverse-transcription initiation and cDNA synthesis platform technology (Argonne National Laboratory Invention Report ANL-IN-94-074; Intellectual property of Regon Molecular Systems, Inc.) for the simple and efficient detection, measurement, cloning, amplification and analysis of biologically expressed sequences - all features build-in the synthesized cDNA. Another technology is the OligoFINGERPRINT technology for genes and libraries fingerprinting by very-short oligonucleotide hybridization (Argonne National Laboratory Invention Report ANL-IN-94-109; Intellectual property of Regon Molecular Systems, Inc.) applicable to microarray-based National Biodefense and pathogen detection programs. The Company provides "open access" to its technology products. For more information, please visit our web site at www.regon-inc.com.
To Contact Us for Technical Reason, To Report Web-Site Link Loose Or Any Other Reason, Please Click Here: uCONTACT Regont
|
